01 Rise of Minimally Invasive ProceduresA prominent trend in the BPH treatment market is the increasing adoption of minimally invasive procedures, which offer reduced recovery times, lower complication rates, and enhanced patient outcomes compared to traditional surgical methods. Techniques such as transurethral resection of the prostate (TURP), laser therapies (e.g., HoLEP), and prostatic artery embolisation (PAE) are gaining traction due to their precision and efficacy. The UroLift system, a prostatic urethral lift, is particularly popular for its office-based application and minimal invasiveness.For instance, in April 2024, Teleflex launched the UroLift 2 System with Advanced Tissue Control, an FDA-cleared upgrade offering laser-etched markers and customisable tissue manipulation for enhanced accuracy, enhancing treatment precision for BPH patients. This trend is driven by patient preference for outpatient procedures and advancements in medical devices, with the Asia-Pacific region showing rapid growth due to medical tourism and improved healthcare access. The shift toward minimally invasive solutions is expected to continue, supported by innovations and increasing physician training.
01 Aging Male PopulationThe global rise in the ageing male population is a primary driver of the BPH treatment market, as BPH prevalence increases significantly with age. According to the National Institute of Diabetes and Digestive and Kidney Diseases, nearly 50% of men aged 51–60 and up to 90% of those over 80 experience BPH symptoms, creating a substantial patient pool. This demographic shift and longer life expectancies amplify demand for pharmacological and surgical treatments.North America, with its advanced healthcare systems, accounted for the largest share of market revenue in 2024, while Asia-Pacific is witnessing rapid growth due to its ageing populations in countries like China and Japan. Innovations like AbbVie’s FDA-approved combination therapy in April 2024, integrating an alpha-blocker and 5-alpha reductase inhibitor, address multiple BPH symptoms, further fueling market expansion. As healthcare awareness and access improve globally, the demand for BPH treatments is expected to surge.
01 High Costs of Advanced TreatmentsA significant restraint in the BPH treatment market is the high cost of advanced treatments, which limits accessibility, particularly in low- and middle-income regions. Procedures like robotic-assisted surgeries and minimally invasive laser therapies can cost upwards of USD 20,000 per procedure, according to the Centres for Medicare & Medicaid Services. These expenses and out-of-pocket medication costs deter patients from seeking optimal care, especially in developing nations with limited healthcare reimbursement policies.Additionally, disparities in healthcare access between urban and rural areas further exacerbated this issue, with many patients relying on less effective traditional treatments. Additionally, the side effects of medications, such as dizziness and sexual dysfunction, can lead to patient noncompliance, hindering market growth. High costs and a lack of awareness about generic alternatives restrict market expansion in budget-sensitive markets. To address this, manufacturers must invest in cost-effective solutions, and governments must enhance reimbursement frameworks.
01 Growth in Emerging MarketsEmerging markets, particularly in Asia-Pacific, present significant opportunities for the BPH treatment market due to rapid demographic changes, improving healthcare infrastructure, and rising medical tourism. The Asia-Pacific region is projected to grow, driven by large ageing populations in countries like China, India, and Japan, where BPH incidence is rising. Government initiatives, such as India’s national men’s health awareness campaign, are increasing early diagnosis and treatment adherence. Key players are capitalising on these opportunities through strategic expansions.Additionally, Olympus Corporation and Astellas Pharma are investing in R&D to develop cost-effective, minimally invasive solutions tailored for emerging markets. The growing adoption of generic drugs and biosimilars further supports market growth by improving affordability. These dynamics and increasing healthcare expenditures position emerging markets as key growth areas for BPH treatment innovations.
September 2025 Laborie expanded its urology product portfolio by introducing enhanced diagnostic and treatment support solutions for lower urinary tract conditions, including technologies used in BPH patient management.
July 2025 Boston Scientific expanded its urology treatment portfolio by strengthening adoption of its Rezūm™ and other minimally invasive BPH therapy solutions through expanded clinical support and physician education programs.
June 2025 Olympus expanded its urology portfolio with advancements in minimally invasive BPH treatment technologies, including enhanced endoscopic solutions designed to improve procedural efficiency and patient outcomes.
May 2025 Teleflex expanded its UroLift® System portfolio by advancing physician training initiatives and expanding access to minimally invasive treatment solutions for benign prostatic hyperplasia (BPH), supporting wider adoption of implant-based prostate procedures.